Zentalis Pharmaceuticals Stock Price

0.00 (0.0%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Zentalis Pharmaceuticals Inc ZNTL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 41.43 20:00:00
Close Price Low Price High Price Open Price Previous Close
Bid Price Ask Price Spread News
38.01 42.49 4.48 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 41.43 USD

Zentalis Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.66B 40.00M 15.53M $ - $ - -2.53 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 8.90%

more financials information »

Zentalis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZNTL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week41.0043.3439.2341.52181,2510.431.05%
1 Month28.2243.3427.1237.00159,74113.2146.81%
3 Months35.5043.3425.4133.81138,4875.9316.7%
6 Months26.5959.3225.4139.74178,55314.8455.81%
1 Year24.6959.3222.0038.09182,41616.7467.8%
3 Years24.6959.3222.0038.09182,41616.7467.8%
5 Years24.6959.3222.0038.09182,41616.7467.8%

Zentalis Pharmaceuticals Description

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.

Your Recent History
Zentalis P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.